Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Key facts

Sponsor

David L Rogers, MD

Principal Investigator

David Rogers, MD

Nationwide Children's Hospital

Intervention

Cerliponase Alfa(drug)

Enrollment

5 enrolled

Eligibility

All sexes

Timeline

2021 – 2027

Study locations (1)

• Nationwide Children's Hospital, Columbus, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for CLN2 disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT05791864
  A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
  Tern Therapeutics, LLC

See all trials for CLN2 disease →